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Ukraine is facing a concentrated human immuno-deficiency virus (HIV) epidemic,1 with a high 
prevalence of HIV in most-at-risk populations 
(MARPs), which include people who inject drugs 
(PWIDs), men who have sex with men (MSM), female 
sex workers (FSWs), street children and sexual partners 
of people from risk groups.2 The scaling up of preven-
tion activities among MARPs is a vital step in con-
trolling and reversing the HIV epidemic. HIV preven-
tion programmes have been in operation since 2004 
to prevent such individuals from acquiring and trans-
mitting HIV infection and to provide HIV care if they 
acquire infection.3 PWID, FSWs, MSM, partners of 
PWIDs, prisoners aged 18 years and street children 
aged between 10 and 19 years are considered to be 
programme clients once they have accessed project 
services and received a unique client code. All clients 
are offered rapid HIV testing and, if found to be 
HIV-positive, are linked to care and support services; if 
found to be HIV-negative, they are advised to repeat 
HIV testing every 6 months.4
Despite the availability of rapid HIV tests, anecdotal 
evidence suggests that a large number of clients are not 
undergoing testing. We also assume that among clients 
who do undergo testing and are found to be HIV-nega-
tive at the initial test, not everyone is undergoing re-
testing. This can hamper early HIV diagnosis, with 
consequent delays in accessing HIV care and treat-
ment, which may lead to increased morbidity, mortal-
ity and continued progression of the HIV epidemic. 
Ensuring that all clients with high-risk behaviour know 
their HIV status and have access to prevention and 
care-related interventions is essential to curb the HIV 
epidemic and achieve the ambitious global goal of 
‘zero HIV infections’ by 2015 and beyond.5
There are no published longitudinal data from 
Ukraine on the exact proportion of clients who were 
tested for HIV at baseline, the proportion who un-
dergo retesting and factors associated with HIV testing 
behaviour of clients, nor is there any published infor-
mation on HIV seroconversion among clients who 
were HIV-negative at initial testing. A huge longitudi-
nal data set has been produced as a result of pro-
gramme data recording. Since 2005, Alliance-Ukraine 
has been using a single registration and monitoring 
system for prevention services, known as the SyrEx da-
tabase.5 This database monitors and analyses data on 
the number of clients covered, distributed materials 
and services provided to clients.
We aimed to describe the performance of HIV pre-
vention programmes and assess factors associated with 
initial HIV testing, retesting and HIV seroconversion 
among clients enrolled in HIV programmes in 
Ukraine. The specific objectives were to 1) assess the 
number (proportion) of clients enrolled in HIV pre-
vention programmes who underwent HIV testing, and 
2) among those who were HIV-negative at initial test-
ing, to assess the number who underwent retesting for 
HIV and the number found to be HIV-positive within 
a year of initial testing. We also assessed specific fac-
tors (age, sex, type of high-risk group, type of service, 
region and number of visits) associated with initial 
testing, retesting and HIV seroconversion.
METHODS
Design
This was a retrospective cohort study of clients en-
rolled in HIV prevention programmes in Ukraine in 
2010–2011.
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Setting: One hundred and forty non-governmental or-
ganisations implementing human immunodeficiency vi-
rus (HIV) prevention programmes among clients, includ-
ing people who inject drugs, prisoners, female sex 
workers, men who have sex with men and street children 
in Ukraine, 2010–2011.
Objective: Among enrolled clients, to assess factors asso-
ciated with HIV testing, HIV retesting within a year of ini-
tial testing and HIV seroconversion.
Design: Retrospective cohort study involving record 
reviews.
Results: Of 192 487 clients, 42 109 (22%) underwent an 
initial HIV test (22% were positive). Among HIV-negative 
clients at baseline, 10 858 (27%) were retested within a 
year: 317 (3%) of these were HIV-positive. HIV testing 
and retesting rates were lower among prisoners (0.3%) 
and others (street children and partners of those in risk 
groups, 6%), and those who did not receive counselling 
or services such as condom and needle distribution. Indi-
viduals who were not counselled were more likely to 
seroconvert.
Conclusions: In this large cohort of high-risk groups 
from Eastern Europe, HIV testing was low and HIV sero-
conversion was high. This is of public health concern, 
bringing into question the overall quality of counselling 
and how well it is tailored to the specific needs of various 
risk groups. Qualitative studies to understand the reasons 
for non-testing are urgently required for designing cli-
ent-specific interventions.
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Setting
Ukraine, with a population of 45 million, has an HIV 
prevalence of 0.27% in the general population. It is es-
timated that about 230 000 people are living with HIV 
in Ukraine, the majority of whom are from high-risk 
groups. Nearly 46% of all HIV-positive individuals reg-
istered in 2012 were PWIDs. With an estimated 
310 000 PWIDs (HIV prevalence 21.6%), 80 000 FSWs 
(HIV prevalence 10%) and 176 000 MSM (HIV preva-
lence 6.4%),2 there is considerable need for HIV pre-
vention services.
To address this need, HIV prevention programmes 
have been widely implemented by local and interna-
tional non-governmental organisations (NGOs) in 
Ukraine since 2004. The International HIV/AIDS Alli-
ance in Ukraine (Alliance-Ukraine), in partnership 
with key civil society and government agencies, is 
leading the response to HIV/AIDS in Ukraine by pro-
viding sub-grants to over 140 local NGOs to imple-
ment a comprehensive package of services for high-
risk groups. This package includes education, 
voluntary counselling and testing (VCT) for HIV, coun-
selling provided by outreach or social workers, includ-
ing promotion of VCT (referred to here as ‘counsel-
ling’), provision of female and male condoms with 
lubricants, needles and syringe distribution, diagnosis 
and treatment of sexually transmitted infections, test-
ing for hepatitis B and C and screening for tuberculo-
sis.4 All services are usually provided by outreach work-
ers, except VCT, which is provided by a physician and 
a nurse at outreach sites or through mobile clinics.
According to data from Alliance-Ukraine, in 2011, 
HIV services reached 157 011 PWIDs (54% of esti-
mated), 28 224 FSWs (40% of estimated), 19 130 MSM 
(20% of estimated) and 25 497 prisoners.6
Each client is advised to undergo HIV testing after 
enrolment.7 HIV testing is voluntary and provided to-
gether with pre- and post-test counselling by a physi-
cian and a nurse at the outreach site. In the case of a 
positive HIV result, the client is advised to undergo a 
confirmatory test, and is referred to the AIDS centre 
for initiation of HIV care, including antiretroviral 
treatment. In the case of a negative result, the client is 
provided with post-test counselling and advised to un-
dergo HIV testing at least once every 6 months or 
within a month of a risk-behaviour incident. Clients 
are advised to present to the prevention services as of-
ten as they wish.
Study population
All clients enrolled into HIV prevention programmes 
in the 2 years from January 2010 to December 2011 
were included in this study. The data cover 24 regions. 
Three regions (Dnipropetrovsk region, Chernivtsi re-
gion and Sevastopol city) were excluded from analysis 
due to technical problems with the data set. The analy-
sis was conducted between March and November 
2013.
Data variables and data source
Information on the following variables was extracted 
from SyrEx for the purpose of the study: unique client 
code, age, sex, primary risk group, initial HIV test re-
sult and date, HIV retesting status (test result) within a 
year of initial test, number of visits over a year from 
the initial test, services provided (needle exchange/
condom distribution/counselling) and region.
Data analysis
Data from SyrEx were extracted and imported into Epi-
Data Version V2.2.2.180 (EpiData Association, Odense, 
Denmark) for analysis. All information entered in Sy-
rEx is de-identified and uses unique codes for each cli-
ent. Data were summarised in means and proportions 
to describe the demographic and clinical profile of the 
clients. Relative risks (RR) with 95% confidence inter-
vals were calculated to assess associations with HIV 
testing, retesting and HIV seroconversion. The χ2 test 
was used to assess statistical significance (P  0.05) 
and χ2 for trend to assess linear trends.
Ethics approval
Ethics approval was obtained from the Ethics Advisory 
Group of the International Union Against Tuberculosis 
and Lung Disease and the Committee on Medical Eth-
ics of the Gromashevskiy Institute of Epidemiology 
and Infectious Diseases of the Ukrainian National 
Academy of Medical Science. As this was a retrospec-
tive review of de-personalised records and involved no 
direct interaction with the study participants, the need 
for informed consent was waived by the ethics 
committees.
RESULTS
Characteristics of the study population
Of 192 487 clients enrolled, 71% were males; the mean 
age of the cohort was 30 years (standard deviation 
10.64). Clients included 118 834 (62%) PWIDs, 30 371 
(16%) prisoners, 19 853 (10%) FSWs, 17 036 (9%) MSM 
and 6392 (3.3%) others (including street children and 
partners of those in risk groups).
Initial human immunodeficiency virus testing and 
retesting within one year
The Figure shows the enrolment, initial HIV testing 
and retesting rates in this population. Of all the clients 
enrolled, 42 109 (22%) underwent an initial HIV test; 
1638 (4%) of these were HIV-positive. Among 10 858 
(27%) who were initially HIV-negative and retested 
within a year, 317 (3%) became HIV positive.
Factors associated with initial human 
immunodeficiency virus testing
Factors associated with initial HIV testing are shown in 
Table 1. Despite receiving counselling from an out-
reach or social worker, which includes VCT promo-
tion, only 29% of clients underwent HIV testing. The 
percentage of clients who received VCT was very low 
(10%). Females were more likely to be tested than 
males, although the difference was minimal (25% vs. 
21%, respectively). Prisoners and others (street chil-
dren and partners of those in risk groups) had the low-
est proportion undergoing initial HIV testing (0.3% 
and 6%, respectively), while MSM had the highest 
(33%). Compared to PWIDs, MSM and FSWs were 
more likely to undergo initial HIV testing, while pris-
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oners and others were less likely. There was a significant linear 
trend associated with uptake of initial HIV testing in regions of 
Ukraine with higher HIV prevalence (χ² for trend 364, P  
0.0001).
Factors associated with retesting for human 
immunodeficiency virus and seroconversion
Factors associated with HIV retesting within a year of initial test-
ing are shown in Table 2. Of 398 clients who were HIV-negative 
on initial HIV testing, only 10 858 (27%) were retested for HIV 
within a year. Higher retesting rates were found among FSWs 
(31%) and in PWIDs (28%), while the lowest retesting propor-
tions were again among prisoners (5%). Provision of counselling 
and condom and needle distribution were associated with a 
higher likelihood of undergoing a second HIV test. Unlike initial 
HIV testing, fewer people in regions with high HIV prevalence 
underwent retesting (26%) than in low-prevalence regions (31%).
Factors associated with HIV seroconversion within one year of 
initial HIV testing are shown in Table 3. Individuals aged 25 
years had a higher risk of HIV seroconversion than younger age 
groups, while FSW had a lower risk of seroconversion than 
FIGURE Enrolment, HIV testing and retesting and seroconversion 
among most at risk populations enrolled in HIV prevention pro-
grammes in Ukraine, 2010–2012. HRG = high-risk group; HIV = hu-
man immunodeficiency virus.
TABLE 1 Factors associated with accepting HIV testing (at baseline) 
among clients enrolled in HIV prevention programmes in Ukraine, 
2010–2011
Category
Total 
n
Tested for HIV 
n (%)* RR (95%CI)
Total 192 487 42 109 (22)
Sex
 Male 136 464 27 955 (21) 1.0
 Female 55 983 14 138 (25) 1.23 (1.21–1.25)
Age, years
 25 53 189 11 980 (23) 1.0
 26-35 90 032 20 675 (23) 0.98 (0.98–0.98)
 36 47 376 9 420 (20) 0.87 (0.87–0.87)
High-risk group
 PWID 118 834 30 173 (25) 1.0
 FSW 19 853 5 821 (30) 1.15 (1.15–1.16)
 MSM 17 036 5 606 (33) 1.30 (1.30–1.30)
 Prisoner 30 371 97 (0.3) 0.01 (0.01–0.01)
 Other 6392 412 (6) 0.25 (0.25–0.25)
Counselling provision† 
 Yes 121 536 35 166 (29) 1.0
 No 70 951 6 943 (10) 0.34 (0.34–0.34)
Region, /100 000‡
 A 120 24 570 4 224 (17) 1.0
 B 120–200 29 963 6 414 (21) 1.25 (1.24–1.25)
 C 200 137 954 31 471 (23) 1.33 (1.33–1.33)
* Percentage rounded to nearest integer.
† Individuals who received counselling provided by the HIV prevention programme.
‡ Ukraine is divided into three regions based on HIV prevalence per 100 000 popula-
tion, where HIV prevention programmes are operational.
HIV = human immunodeficiency virus; RR = relative risk; CI = confidence interval; 
PWID = people who inject drugs; FSW = female sex worker; MSM = men who have 
sex with men.
TABLE 2 Factors associated with retesting for HIV within a year of 
initial HIV testing among clients enrolled in HIV prevention 
programmes in Ukraine, 2010–2011
Category
Total 
n
Retested for HIV 
n (%)* RR (95%CI)
Total 40 398 10 858 (27)
Sex
 Male 26 805 6 851 (26) 1.0
 Female 13 577 4 003 (30) 1.15 (1.15–1.15) 
Age, years
 25 11 697 2 961 (25) 1.0
 25-35 19 849 5 439 (27) 1.08 (1.08–1.08) 
 35 8 819 2 453 (28) 1.02 (1.01–1.02) 
High-risk group
 PWID 28 757 8 185 (28) 1.0
 FSW 5 682 1 755 (31) 1.09 (1.08–1.09) 
 MSM 5 471 837 (15) 0.54 (0.54–0.54) 
 Prisoner 95 5 (5) 0.18 (0.13–0.27) 
 Other 393 76 (19) 0.68 (0.66–0.70) 
Counselling provision†
 Yes 33 745 9 612 (28) 1.0 
 No 6 653 1 246 (19) 0.66 (0.66–0.66) 
Condom distribution
 Yes 37 146 10 282 (28) 1.0
 No 3 252 576 (18) 0.64 (0.64–0.64) 
Needle distribution‡
 Yes 27 032 7 770 (29) 1.0
 No 1 725 415 (24) 0.84 (0.83–0.84) 
Region, /100 000§
 120 4 111 1 270 (31) 1.0
 120-200 6 084 1 651 (27) 0.88 (0.88–0.88) 
 200 30 203 7 937 (26) 0.85 (0.85–0.85) 
* Percentage rounded to nearest integer.
† Individuals who received counselling provided by the HIV prevention programme.
‡ Only among PWIDs (n = 28 757).
§ Ukraine is divided into three regions based on HIV prevalence per 100 000 popula-
tion, where HIV prevention programmes are operational.
HIV = human immunodeficiency virus; RR = relative risk; CI = confidence interval; 
PWID = people who inject drugs; FSW = female sex worker; MSM = men who have 
sex with men.
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PWIDs. Individuals who did not receive counselling were more 
likely to seroconvert than those who were counselled. Clients 
from regions with overall HIV prevalence ranging from 120 to 
200 HIV cases per 100 000 population were 12 times more likely 
to become HIV-positive in 12 months than those from regions 
with an overall HIV prevalence of 120/100 000. Clients from re-
gions with overall HIV prevalence 200/100 000 were five times 
more likely to seroconvert in 12 months. Neither condom nor sy-
ringe distribution were significantly associated with seroconver-
sion, but this may be partly due to the fact that most clients re-
ceived these services.
DISCUSSION
This study is the first attempt to analyse one of the largest cohorts 
of high-risk groups in an Eastern European country. It included 
prospective follow-up data on almost one fifth of a million vul-
nerable and excluded persons. This is a laudable achievement, 
and is an example of how NGOs can effectively contribute to HIV 
prevention within a hard-to-reach population where access to 
conventional health services is problematic and HIV transmission 
is intense.
A strength of this study is that it used aggregated and stan-
dardised data from 140 NGOs working with MARPs in Ukraine. 
Standard data collection forms were used to gather data and there 
was a system of quarterly monitoring, reporting and data quality 
control procedures in place. We thus believe that the data are ro-
bust. As the study was collected from settings where MARPs are 
concentrated, it is also likely to reflect the reality in the field. This 
is an example of how routine monitoring data collected through 
standardised software systems can contribute to knowledge about 
the HIV epidemic and the effectiveness of preventive strategies. 
This can be a valuable addition to knowledge produced through 
integrated bio-behavioural surveys and operational studies.
A discouraging finding was that only two in ten individuals 
underwent initial HIV testing and no more than three in ten un-
derwent retesting within a year of the initial test—a waterfall re-
duced to a trickle. As HIV testing is a critical path to offering pre-
vention and care to MARPs, this is of serious public health 
concern, and HIV prevention programmes must rethink their out-
reach HIV testing strategies.
Several findings of this study are of public health importance. 
First, HIV positivity among those initially tested for HIV was 
3.9%, which seems low in a context where groups such as PWIDs 
and FSWs are known to have a high prevalence, of 22% and 10%, 
respectively.8,9 The reasons may be that those who know their 
HIV status do not attend for HIV testing and that many who feel 
they might be HIV-positive avoid HIV testing sites due to fear of 
breaching confidentiality and peer stigmatisation.
On the other hand, HIV prevalence among those who under-
went retesting within 12 months was 2.9%; this seems high, and 
may indicate continuing high-risk behaviour and recent HIV out-
breaks. As overall retesting rates are low, it is also possible that 
those who return for testing are more likely to have risk be-
haviours. Regions with average HIV prevalence in the general 
population have higher seroconversion rates than those with 
high prevalence. This may be explained by a higher concentra-
tion and longer history of HIV prevention programmes in 
high-prevalence regions, which may have had a positive influ-
ence in reducing clients’ risk behaviour over time. Network-re-
lated mechanisms may also influence seroconversion.10 This find-
ing suggests that HIV prevention should be strengthened in 
regions with average HIV prevalence.
Second, even among those who underwent HIV counselling, 
only three in ten individuals underwent initial HIV testing. This 
undermines the effectiveness of counselling in terms of HIV test-
ing promotion. We might need to deal with HIV testing stigmati-
sation and breach of confidentiality, as well as other fears about 
the use of HIV services.11 Offering psychological support and sex- 
and age-specific services as part of the essential package of care 
and client-tailored counselling may be required to improve HIV 
testing in general. This is a critical area requiring a review of 
counselling approaches.
Third, prisoners and others (street children and partners of 
high-risk groups) had a significantly lower likelihood of being 
tested and retested, and this may reflect difficulties related to ac-
cess. It is difficult to reach prisoners due to administrative barriers 
and punitive laws. Closer collaboration with prison authorities 
and informal prison community leaders is essential. Educational 
programmes focusing on the benefits of HIV testing and early 
treatment initiation as well stigma reduction campaigns might 
improve testing rates in prisons, but this needs to be evaluated in 
TABLE 3 Factors associated with HIV seroconversion within a year 
of initial HIV testing among clients enrolled in HIV prevention 
programmes in Ukraine, 2010–2011
Category
Total 
n
HIV-positive 
clients 
n (%)* RR (95%CI)
Total 10 858 317 (2.9)
Sex
 Male 6 851 212 (3.1) 1.0
 Female 4 003 105 (2.6) 0.85 (0.72–1.00)
Age, years
 25 2 961 53 (1.8) 1.0
 25–35 5 439 156 (2.9) 1.60 (1.18–2.18)
 35 2 345 108 (4.4) 2.45 (1.77–3.40)
High-risk group
 PWID 8 185 264 (3.2) 1.0
 FSW 1 755 23 (1.3) 0.41 (0.27–0.62)
 MSM 837 26 (3.1) 0.96 (0.65–1.43)
 Prisoner 5 0 (0.0) NA
 Other 76 4 (5.3) 1.63 (0.62–4.27)
Counselling provision†
 Yes 9 612 266 (2.8) 1.0
 No 1 246 51 (4.1) 1.48 (1.10–1.98)
Condom distribution
 Yes 10 282 299 (2.9) 1.0
 No 576 18 (3.1) 1.07 (0.67–1.72)
Needle distribution‡ 
 Yes 7 770 249 (3.2) 1.0
 No 415 15 (3.6) 1.13 (0.68–1.88)
Region, /100 000§
 120 1 270 6 (0.5) 1.0
 120–200 1 651 97 (5.9) 12.44 (5.47–28.27)
 200 7 937 214 (2.7) 5.71 (2.54–12.82)
* Percentage rounded to nearest integer.
† Individuals who received counselling provided by the HIV prevention programme.
‡ Only among PWIDs (n = 28 757).
§ Ukraine is divided into three regions based on HIV prevalence per 100 000 popula-
tion, where HIV prevention programmes are operational.
HIV = human immunodeficiency virus; RR = relative risk; CI = confidence interval; 
PWID = people who inject drugs; FSW = female sex worker; MSM = men who have 
sex with men.
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an operational setting. The migratory nature of street children is a 
serious challenge; psychological difficulties and the legal restric-
tions related to working with underage groups may influence the 
effectiveness of counselling messages. This warrants specific quali-
tative research to tailor prevention in this sub-group.
Fourth, FSWs were more likely to undergo initial HIV testing 
and retesting and were less likely to seroconvert than PWIDs. This 
may be because ongoing HIV prevention activities, and in partic-
ular the organisation of HIV testing, are better suited to FSWs 
than PWIDs. FSWs reportedly prioritise their health and express a 
need for testing services.12 HIV testing should be adapted to in-
crease uptake by PWIDs. The observed higher seroconversion 
among PWIDs may be the result of ongoing HIV transmission 
through sharing contaminated needles, and continued attention 
to safer injecting practices is required, despite encouraging data 
that 95.5% of PWIDs had used sterile equipment for their last 
injection.9
Finally, it is well known that HIV testing in MARPs requires 
multiple approaches, including night-time (moonlight) testing, 
mobile outreach, community engagement, activism and advo-
cacy.13 In many cases, this is actually taking place on the ground, 
but the data suggest that effectiveness is still low. Current ap-
proaches may thus need to be reviewed and further adapted.
One of the main limitations of this study is that we do not 
have data on the HIV status of those who did not retest for HIV. 
In addition, retesting rates are low and seroconversion rates may 
not be generalisable. Data on risk group characteristics are also 
limited and do not include additional risk information, such as 
injecting drug use and engagement in sex work, which might 
have an effect on HIV seroconversion.
In conclusion, achieving the UNAIDS objective of ‘getting to 
zero’ new HIV infections by 2015 and beyond requires priority 
actions targeting high-risk group populations. Failing to address 
this will lead to continued intense HIV transmission within high-
risk groups, and a risk of transmission to the general population, 
a trend that is already visible in Ukraine.
This study shows that only a very limited proportion of MARPs 
in Ukraine currently undergo HIV testing, and that HIV serocon-
version rates are substantial, indicating the need for urgent atten-
tion and focused interventions. Several challenges have been 
identified and ways forward suggested.
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Contexte  :  Cent quarante organisations non gouvernementales 
impliquées dans la mise en œuvre de programmes de prévention du 
virus de l’immunodéficience humaine (VIH) pour des clients 
comprenant des utilisateurs de drogues injectables, des détenus, des 
travailleuses du sexe, des homosexuels masculins et des enfants des 
rues en Ukraine de 2010 à 2011.
Objectif  :  Evaluer les facteurs associés au dépistage du VIH, à un 
second dépistage dans l’année qui suit et à une séroconversion parmi 
les clients enrôlés.
Schéma  :  Etude rétrospective de cohorte par revue de dossiers.
Résultats  :  Sur 192 487 clients, 42 109 (22%) ont eu un test VIH 
initial (22% étaient positifs). Parmi les clients négatifs au départ, 
10 858 (27%) ont eu un deuxième test dans l’année, dont 317 (3%) 
se sont révélés VIH positifs. Les taux de dépistage initial et subséquent 
étaient plus faibles parmi les prisonniers (0,3%) et d’autres groupes 
comme les enfants des rues et les partenaires de groupes à risque 
(6%), ainsi que ceux qui n’avaient pas bénéficié de conseil ni de 
services comme la distribution de préservatifs et d’aiguilles. Les sujets 
qui n’avaient pas bénéficié de conseil étaient plus enclins à la 
séroconversion.
Conclusions  :  Dans cette vaste cohorte de groupes à risque élevé 
d’Europe de l’Est, le taux de dépistage était faible et le taux de 
séroconversion élevé. Cette situation est préoccupante en termes de 
santé publique et met en doute la qualité d’ensemble du conseil et la 
manière dont il est adapté aux besoins spécifiques de divers groupes 
à risque. Il est urgent de réaliser des études qualitatives afin de 
comprendre les raisons du non dépistage et d’élaborer des 
interventions spécifiques des clients.
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Marco de referencia: Las 140 organizaciones no gubernamentales 
que aplican programas de prevención de la infección por el virus de 
la inmunodeficiencia humana (VIH) a usuarios como los consumidores 
de drogas inyectables, los reclusos, las trabajadoras del sexo, los 
hombres que tienen relaciones sexuales con hombres y los niños de 
la calle en Ucrania entre el 2010 y el 2011.
Objetivo: Evaluar los factores que se asocian con la práctica de la 
prueba diagnóstica del VIH, la repetición de la prueba un año 
después de la primera y la seroconversión en los usuarios inscritos.
Método: Fue este un estudio retrospectivo de cohortes con análisis 
de las historias clínicas.
Resultados: De los 192 487 usuarios del programa, 42 109 
recibieron una primera prueba del VIH (22%); 22% fueron positivos. 
De las personas con un resultado negativo inicial, 10 858 repitieron 
la prueba un año después (27%) y 317 de ellas obtuvieron un 
resultado positivo (3%). Las tasas de práctica de la prueba del VIH y 
de repetición de la misma fueron inferiores en los reclusos (0,3%), 
en el grupo de otros (los niños de la calle y las parejas de personas 
de los grupos de riesgo, 6%) y en las personas que no recibieron 
asesoramiento ni servicios como la distribución de agujas o 
preservativos. La seroconversión fue más frecuente en las personas 
que no recibieron orientación.
Conclusión: En este amplio estudio de cohortes de grupos de 
riesgo en Europa oriental, la tasa de pruebas diagnósticas del VIH 
fue baja y los índices de seroconversión fueron altos. Esta situación 
representa un problema de salud pública y pone en tela de juicio la 
calidad general de los programas de asesoramiento y la forma como 
estos se adaptan a las necesidades específicas de los diversos grupos 
de riesgo. Se precisan con urgencia estudios cualitativos que 
analicen las razones de la falta de la prueba diagnóstica, con el fin 
de elaborar intervenciones que sean específicas para determinados 
usuarios.
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